Y Intercept Hong Kong Ltd Sells 4,183 Shares of argenex SE $ARGX

Y Intercept Hong Kong Ltd trimmed its stake in shares of argenex SE (NASDAQ:ARGX) by 84.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 750 shares of the company’s stock after selling 4,183 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in argenex were worth $553,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in shares of argenex by 32.1% during the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after buying an additional 122 shares during the period. NewEdge Advisors LLC boosted its position in shares of argenex by 5,962.5% in the first quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after acquiring an additional 1,431 shares during the period. Focus Partners Wealth grew its stake in argenex by 22.3% during the first quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after acquiring an additional 73 shares in the last quarter. Geneos Wealth Management Inc. increased its holdings in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock worth $69,000 after acquiring an additional 99 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in argenex by 2.6% during the 2nd quarter. Janney Montgomery Scott LLC now owns 1,171 shares of the company’s stock worth $645,000 after acquiring an additional 30 shares during the period. Institutional investors own 60.32% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ARGX shares. Stifel Nicolaus raised their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Morgan Stanley lifted their price objective on argenex from $1,070.00 to $1,110.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Robert W. Baird lowered argenex from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 18th. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Royal Bank Of Canada boosted their price objective on argenex from $860.00 to $925.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $986.78.

argenex Trading Up 1.9%

ARGX opened at $851.72 on Wednesday. The stock has a market capitalization of $52.70 billion, a P/E ratio of 36.57, a PEG ratio of 0.72 and a beta of 0.37. The stock has a 50-day moving average price of $849.37 and a 200-day moving average price of $788.27. argenex SE has a 12-month low of $510.05 and a 12-month high of $934.62.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.